"The global cholesterol-lowering drugs market will reach $24.63bn in 2019 says visiongain report"

LONDON - March 9, 2016 - PRLog -- The Cholesterol-Lowering Drugs market will reach $24.63bn in 2019 predicts new visiongain report

A new report by visiongain predicts that the global cholesterol-lowering drugs market will reach $24.63bn in 2019. This forecast and others appear in Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists, published in October 2015. Visiongain is a business information provider based in London, UK.

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists report examines the current and future trends in the cholesterol-lowering drugs market. High cholesterol levels are present in a large percentage of the world’s population, leading to an increasing level of cardiovascular diseases. The important of managing cholesterol levels has become increasingly important to healthcare professionals in recent years, and the demand for more effective treatments has grown accordingly. A raft of new, more efficacious therapies is entering the market and these are forecast to lift revenues for the sector, with these medicines able to treat patients who have resisted current treatments.

In this report, we examine in detail a number of key national markets, as well as the sales of a wide range of leading cholesterol-lowering drugs in the following submarkets: statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs. Forecasts are also provided for leading products in each submarket. Using our experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national markets and treatment areas, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the cholesterol-lowering drugs market. This includes a look at their current products, as well those presently in development. Recent financial performance is analysed, along with a breakdown of each company’s leading products and an analysis of news that may influence the course of the company.

Jack Evans, a pharmaceutical and medical devices industry analyst in visiongain, said: “The long-awaited market launch of PCSK9 inhibitors in 2015 could lead to a revolution in the treatment of patients with hypercholesterolaemia, even if these drugs are reserved for a select subgroup of patients.”

Visiongain’s report provides revenue forecasts to 2025 for the cholesterol-lowering drugs market and its leading national markets. The report discusses selected leading companies which hold significant shares of the market. These companies include AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, Abbvie, Novartis, Sanofi and Amgen.

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.